Arbutus Biopharma (NASDAQ:ABUS) Stock, Quote.Headers.trade-ideas

Arbutus Biopharma

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

BZ_briefs

Biotech

Large Cap

News

Health Care

Legal

Movers

Trading Ideas

General

ABUS

MRNA

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

vaccine ai

Technicals

Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead

covid vaccine shutter

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.

Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

<p>Owning a home can give some people confidence about their retirement prospects, but experts warn that this confidence might be misplaced.</p>
<p>According to the Your Money Retirement Survey conducted by SurveyMonkey and CNBC.com, about 37% of workers – including those employed part-time, full-time, self-employed, or as business owners – believe they are "ahead of schedule" (7%) or "on schedule" (30%) with their retirement savings.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"><strong> </strong><strong>Here are three ways to join the club.</strong></a></strong></li>
<li><strong>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"><strong> you can become part of the next big real estate boom today.</strong></a></strong></li>
<li><strong>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"><strong> </strong><strong>Here's how you can invest in the city before that happens</strong></a>.</strong></li>
</ul>
<p>Among those who feel on track, 42% attribute their progress to starting<a href="https://www.benzinga.com/personal-finance/24/05/38793057/can-you-guess-how-many-retire-with-a-5-million-nest-egg"> retirement savings</a> early. Other key factors contributing to their preparedness include having little to no debt (38%) and home equity or ownership (37%).</p>
<p>The August survey gathered responses from 6,657 adults, including 2,603 retirees and 4,054 working adults.</p>
<p><strong><em>See Also: </em></strong><strong><em>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong><em> </em></strong><strong><em>How do you compare</em></strong></a>?</em></strong></p>
<p>Angie Chen, a senior research economist and assistant director of savings research at the Center for Retirement Research at Boston College, suggests that homeowners' confidence in their home's value as a source of retirement wealth may be misguided.</p>
<p>"Homeowners are actually more likely to be overconfident in their retirement readiness," Chen told CNBC. "There's a lot of misconception in terms of how people assess whether they are ahead or not in retirement."</p>
<p>Nevertheless, Winnie Sun, co-founder and managing director of Sun Group Wealth Partners in Irvine, California, points out that homeownership can offer other benefits during retirement.</p>
<p><strong>Trending: </strong><strong>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"><strong> </strong><strong>here's how you can join for $10.</strong></a></strong></p>
<p>The Center for Retirement Research's (CRR) National Retirement Risk Index (NRRI) gauges the percentage of working-age households at risk of being financially unprepared for retirement. A 2023 CRR analysis revealed that 28% of people believe they are not at risk, despite the NRRI indicating otherwise.</p>
<p>"People who own houses but still owe a lot on their houses are much more likely to be overconfident or not worried enough," Chen said.</p>
<p><strong>Trending: </strong><strong>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"><strong> </strong><strong>become a landlord in just 10 minutes, and you only need $100</strong></a>.</strong></p>
<p>To accurately assess retirement preparedness, Chen emphasizes the importance of considering not just the value of your home but also the amount you have borrowed and still owe.</p>
<p>For instance, if you purchased a $500,000 home but still owe $400,000, your actual equity is $100,000. Experts caution that accessing this equity can be costly and risky, as borrowing against your home is not always straightforward.</p>
<p>"<a href="https://www.benzinga.com/personal-finance/24/06/39234360/my-struggling-73-year-old-dad-owes-45-000-on-his-mortgage-and-15-000-on-a-heloc-should-he-sell-o">Housing is not liquid</a>," Chen said. "You might feel good about having this large asset, but you can't consume that in retirement. You can't spend it so that you can spend and consume other savings."</p>
<p><strong>Trending: </strong><strong>Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"><strong> </strong><strong>re-engineers traditional banking with this new high-yield account — start saving better today.</strong></a></strong></p>
<p>Experts also point out some advantages to homeownership.</p>
<p>Owning a home offers financial benefits even if you're not factoring in home equity for retirement. First, you build equity in your home. Sun said that when you sell the property, such as when downsizing in retirement, you can access that equity as a lump sum.</p>
<p>Additionally, while you own the property, you have a fixed housing cost, typically including a stable mortgage payment. Despite rising costs for home insurance and property taxes in recent years, you might be eligible for senior discounts on utilities by the time you retire.</p>
<p>Although a house is not a liquid asset, experts suggest you can still access your home equity if needed.</p>
<p>"In most cases for retirees, they kind of see equity as their emergency fund," Sun said.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong> </strong><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"><strong> </strong><strong>The percentage may shock you</strong></a>.</strong></li>
<li><strong><a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv"><strong>IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</strong></a></strong></li>
</ul>


Personal Finance

Retirement Ready? Think Again As Experts Warn Homeowners Still Paying Mortgages That They 'Are Much More Likely To Be Overconfident'

<p>Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has outperformed the market over the past 5 years by 11.84% on an annualized basis producing an average annual return of 25.79%. Currently, Oracle has a market capitalization of $465.52 billion. </p>
<p><strong>Buying $1000 In ORCL:</strong> If an investor had bought $1000 of ORCL stock 5 years ago, it would be worth <strong>$3,109.96</strong> today based on a price of $168.00 for ORCL at the time of writing.</p>
<h3>Oracle's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726867809_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ORCL

Here's How Much You Would Have Made Owning Oracle Stock In The Last 5 Years

<p>In the latest quarter, 4 analysts provided ratings for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ADMA Biologics and provided 12-month price targets. The average target is $18.25, accompanied by a high estimate of $20.00 and a low estimate of $15.00. Marking an increase of 32.73%, the current average surpasses the previous average price target of $13.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866079_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive ADMA Biologics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ADMA Biologics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of ADMA Biologics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into ADMA Biologics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ADMA Biologics analyst ratings.</strong></a></p>
<h2>Get to Know ADMA Biologics Better</h2>
<p>ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.</p>
<h3>Understanding the Numbers: ADMA Biologics's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> ADMA Biologics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>78.29%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> ADMA Biologics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>29.91%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ADMA Biologics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>18.75%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> ADMA Biologics's ROA excels beyond industry benchmarks, reaching <strong>8.82%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.75</strong>, ADMA Biologics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ADMA

In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics

<p>In the last three months, 10 analysts have published ratings on Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Renasant, presenting an average target of $36.9, a high estimate of $41.00, and a low estimate of $32.00. Observing a 7.83% increase, the current average has risen from the previous average price target of $34.22. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866068_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Renasant among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Bishop</td>
<td>Hovde Group</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Renasant. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Renasant compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Renasant's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Renasant's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RNST/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Renasant analyst ratings.</strong></a></p>
<h2>About Renasant</h2>
<p>Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: community banks, insurance, and wealth management. With its community banks segment, the company provides a range of financial services to individuals and small businesses. Its insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The wealth management segment provides a range of services including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment. Renasant Corporation operates in the southern United States.</p>
<h3>Financial Insights: Renasant</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Renasant's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>11.09%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Renasant's net margin excels beyond industry benchmarks, reaching <strong>23.72%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Renasant's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.66%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Renasant's ROA excels beyond industry benchmarks, reaching <strong>0.22%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.28</strong>, Renasant adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RNST

A Closer Look at 10 Analyst Recommendations For Renasant

<p>Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Cathay General and provided 12-month price targets. The average target is $44.5, accompanied by a high estimate of $50.00 and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 11.95% increase from the previous average price target of $39.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866059_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Cathay General is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Underweight</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cathay General. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cathay General compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Cathay General's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cathay General's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CATY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cathay General analyst ratings.</strong></a></p>
<h2>All You Need to Know About Cathay General</h2>
<p>Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities, and advisory services.</p>
<h3>Cathay General's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Cathay General's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-12.76%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Cathay General's net margin excels beyond industry benchmarks, reaching <strong>37.43%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Cathay General's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.4%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Cathay General's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.29%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Cathay General's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.12</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CATY

Unveiling 4 Analyst Insights On Cathay General

<p>During the last three months, 4 analysts shared their evaluations of First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $36.5, with a high estimate of $40.00 and a low estimate of $31.00. This upward trend is apparent, with the current average reflecting a 9.77% increase from the previous average price target of $33.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866050_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of First Finl Bankshares among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to First Finl Bankshares. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Finl Bankshares compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of First Finl Bankshares's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into First Finl Bankshares's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FFIN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on First Finl Bankshares analyst ratings.</strong></a></p>
<h2>Discovering First Finl Bankshares: A Closer Look</h2>
<p>First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.</p>
<h3>Financial Insights: First Finl Bankshares</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, First Finl Bankshares showcased positive performance, achieving a revenue growth rate of <strong>7.11%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> First Finl Bankshares's net margin is impressive, surpassing industry averages. With a net margin of <strong>40.04%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.49%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.4%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FFIN

Analyst Ratings For First Finl Bankshares

<p>6 analysts have shared their evaluations of Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $47.33, a high estimate of $57.00, and a low estimate of $38.00. This current average reflects an increase of 13.15% from the previous average price target of $41.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866035_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Live Oak Bancshares among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Timothy Switzer</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Live Oak Bancshares. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Live Oak Bancshares compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Live Oak Bancshares's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LOB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Live Oak Bancshares analyst ratings.</strong></a></p>
<h2>All You Need to Know About Live Oak Bancshares</h2>
<p>Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.</p>
<h3>Unraveling the Financial Story of Live Oak Bancshares</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Live Oak Bancshares's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.27%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Live Oak Bancshares's net margin excels beyond industry benchmarks, reaching <strong>21.85%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Live Oak Bancshares's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.86%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Live Oak Bancshares's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.23%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Live Oak Bancshares's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.12</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 6 Analyst Projections For Live Oak Bancshares

<p>Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 10 years by 21.34% on an annualized basis producing an average annual return of 32.55%. Currently, Coca-Cola Consolidated has a market capitalization of $11.08 billion. </p>
<p><strong>Buying $1000 In COKE:</strong> If an investor had bought $1000 of COKE stock 10 years ago, it would be worth <strong>$16,450.88</strong> today based on a price of $1264.25 for COKE at the time of writing.</p>
<h3>Coca-Cola Consolidated's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866016_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


COKE

Here's How Much You Would Have Made Owning Coca-Cola Consolidated Stock In The Last 10 Years

<p>Across the recent three months, 12 analysts have shared their insights on Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.67, a high estimate of $28.00, and a low estimate of $21.00. Marking an increase of 7.59%, the current average surpasses the previous average price target of $22.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866015_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Regions Finl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kenneth Usdin</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Regions Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Regions Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Regions Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Regions Finl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Regions Finl analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Regions Finl</h2>
<p>Regions Financial is a regional bank headquartered in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.</p>
<h3>Regions Finl: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Challenges:</strong> Regions Finl's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-11.55%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>27.56%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Regions Finl's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.09%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Regions Finl's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.31%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Regions Finl's debt-to-equity ratio is below the industry average at <strong>0.36</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


12 Analysts Have This To Say About Regions Finl

<p>Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) has outperformed the market over the past 15 years by 13.06% on an annualized basis producing an average annual return of 24.88%. Currently, Gartner has a market capitalization of $39.86 billion. </p>
<p><strong>Buying $1000 In IT:</strong> If an investor had bought $1000 of IT stock 15 years ago, it would be worth <strong>$28,516.94</strong> today based on a price of $517.24 for IT at the time of writing.</p>
<h3>Gartner's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726866011_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Gartner Stock In The Last 15 Years

<p>Deep-pocketed investors have adopted a bullish approach towards Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Caterpillar. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 45% leaning bullish and 36% bearish. Among these notable options, 14 are puts, totaling $1,288,875, and 8 are calls, amounting to $389,403.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $310.0 and $450.0 for Caterpillar, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Caterpillar options trades today is 723.82 with a total volume of 11,962.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Caterpillar's big money trades within a strike price range of $310.0 to $450.0 over the last 30 days.</p>
<h3>Caterpillar Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726865250_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$9.15</td>
<td>$9.0</td>
<td>$9.07</td>
<td>$350.00</td>
<td>$546.3K</td>
<td>1.2K</td>
<td>634</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.65</td>
<td>$5.3</td>
<td>$5.65</td>
<td>$450.00</td>
<td>$141.2K</td>
<td>136</td>
<td>250</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$7.55</td>
<td>$6.85</td>
<td>$6.85</td>
<td>$350.00</td>
<td>$123.3K</td>
<td>27</td>
<td>200</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$9.05</td>
<td>$8.95</td>
<td>$9.02</td>
<td>$350.00</td>
<td>$95.5K</td>
<td>1.2K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$8.8</td>
<td>$8.75</td>
<td>$8.79</td>
<td>$350.00</td>
<td>$89.7K</td>
<td>1.2K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Caterpillar</h3>
<p>Caterpillar is the top manufacturer of heavy equipment, power solutions, and locomotives. It is currently the world's largest manufacturer of heavy equipment. The company is divided into four reportable segments: construction industries, resource industries, energy and transportation, and Cat Financial. Its products are available through a dealer network that covers the globe with about 2,700 branches maintained by 160 dealers. Cat Financial provides retail financing for machinery and engines to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Caterpillar product sales.</p>
<p>Following our analysis of the options activities associated with Caterpillar, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Caterpillar</h3>
<ul>
<li>With a volume of 5,177,212, the price of CAT is down -1.13% at $369.1. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 39 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Caterpillar options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

What the Options Market Tells Us About Caterpillar

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Visa</strong>.</p>
<p>Looking at options history for Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) we detected 19 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 52% with bearish.</p>
<p>From the overall spotted trades, 15 are puts, for a total amount of $875,964 and 4, calls, for a total amount of $279,465.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $300.0 for Visa over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Visa stands at 446.8, with a total volume reaching 1,862.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Visa, situated within the strike price corridor from $230.0 to $300.0, throughout the last 30 days.</p>
<h3>Visa Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726865245_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$34.55</td>
<td>$33.75</td>
<td>$34.0</td>
<td>$250.00</td>
<td>$170.0K</td>
<td style="text-align: right;">229</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.0</td>
<td>$18.75</td>
<td>$18.8</td>
<td>$300.00</td>
<td>$99.5K</td>
<td style="text-align: right;">49</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$14.25</td>
<td>$14.0</td>
<td>$14.14</td>
<td>$295.00</td>
<td>$77.9K</td>
<td style="text-align: right;">340</td>
<td style="text-align: right;">343</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$14.1</td>
<td>$13.8</td>
<td>$13.99</td>
<td>$295.00</td>
<td>$77.4K</td>
<td style="text-align: right;">340</td>
<td style="text-align: right;">288</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.25</td>
<td>$15.45</td>
<td>$295.00</td>
<td>$69.5K</td>
<td style="text-align: right;">129</td>
<td style="text-align: right;">154</td>
</tr>
</tbody>
</table>
</p>
<h3>About Visa</h3>
<p>Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.</p>
<p>Having examined the options trading patterns of Visa, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Visa</h3>
<ul>
<li>With a volume of 27,553,349, the price of V is down -0.43% at $284.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 32 days.</li>
</ul>
<h3>What Analysts Are Saying About Visa</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $314.6666666666667.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Compass Point lowers its rating to Buy with a new price target of $319.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Visa, targeting a price of $308.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Visa with a target price of $317. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Visa with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Visa's Options Frenzy: What You Need to Know

<p>Benzinga's options scanner just detected over 8 options trades for <strong>JD.com</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) summing a total amount of $1,462,072.</p>
<p>At the same time, our algo caught 4 for a total amount of 1,325,899.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $30.0 for JD.com during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for JD.com's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JD.com's whale activity within a strike price range from $25.0 to $30.0 in the last 30 days. </p>
<h3>JD.com Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726865239_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.75</td>
<td>$3.65</td>
<td>$3.66</td>
<td>$30.00</td>
<td>$1.0M</td>
<td>230</td>
<td>3.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.96</td>
<td>$0.94</td>
<td>$0.94</td>
<td>$25.00</td>
<td>$94.0K</td>
<td>22.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.99</td>
<td>$0.94</td>
<td>$0.94</td>
<td>$25.00</td>
<td>$94.0K</td>
<td>22.3K</td>
<td>1</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.05</td>
<td>$1.03</td>
<td>$1.06</td>
<td>$27.50</td>
<td>$54.6K</td>
<td>31.4K</td>
<td>875</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$1.0</td>
<td>$0.96</td>
<td>$0.99</td>
<td>$27.50</td>
<td>$52.9K</td>
<td>31.4K</td>
<td>2.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About JD.com</h3>
<p>JD.com is a leading e-commerce platform with its 2022 China GMV being similar to Pinduoduo (GMV not reported), on our estimate, but still lower than Alibaba. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.</p>
<p>Having examined the options trading patterns of JD.com, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of JD.com</h3>
<ul>
<li>Trading volume stands at 9,633,570, with JD's price down by -0.56%, positioned at $28.58.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 54 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for JD.com, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About JD.com

FLUMIST Receives Approval For Self-Administration In U.S.

Dividends

IDACORP Increases Common Stock Dividend From $0.83 To $0.86

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Trade Desk</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TTD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Trade Desk.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 25% bullish and 75%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $808,150, and 4 are calls, for a total amount of $244,857.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $115.0 for Trade Desk over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Trade Desk options trades today is 754.25 with a total volume of 633.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Trade Desk's big money trades within a strike price range of $50.0 to $115.0 over the last 30 days.</p>
<h3>Trade Desk Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726864342_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$15.05</td>
<td>$14.4</td>
<td>$15.02</td>
<td>$115.00</td>
<td>$600.8K</td>
<td>208</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.9</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$100.00</td>
<td>$143.0K</td>
<td>440</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$4.55</td>
<td>$4.35</td>
<td>$4.52</td>
<td>$105.00</td>
<td>$118.4K</td>
<td>2.4K</td>
<td style="text-align: right;">401</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$19.6</td>
<td>$19.2</td>
<td>$19.2</td>
<td>$90.00</td>
<td>$57.6K</td>
<td>1.3K</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$22.7</td>
<td>$21.6</td>
<td>$21.6</td>
<td>$90.00</td>
<td>$43.2K</td>
<td>451</td>
<td style="text-align: right;">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>After a thorough review of the options trading surrounding Trade Desk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,241,277, with TTD's price down by -0.57%, positioned at $109.51.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>What Analysts Are Saying About Trade Desk</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $119.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Loop Capital persists with their Buy rating on Trade Desk, maintaining a target price of $120.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $115.<br />
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $135.<br />
&#x2A; An analyst from Wedbush persists with their Outperform rating on Trade Desk, maintaining a target price of $115.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $110.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Trade Desk: Analyzing the Surge in Options Activity

<p>Financial giants have made a conspicuous bullish move on Carvana. Our analysis of options history for Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) revealed 24 unusual trades.</p>
<p>Delving into the details, we found 62% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $609,015, and 12 were calls, valued at $2,048,631.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $250.0 for Carvana over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Carvana's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Carvana's whale activity within a strike price range from $70.0 to $250.0 in the last 30 days. </p>
<h3>Carvana 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726864336_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$26.9</td>
<td>$24.35</td>
<td>$26.67</td>
<td>$146.00</td>
<td>$1.3M</td>
<td>3.8K</td>
<td>3.0K</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$69.4</td>
<td>$68.05</td>
<td>$69.4</td>
<td>$105.00</td>
<td>$138.8K</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$2.24</td>
<td>$2.03</td>
<td>$2.04</td>
<td>$180.00</td>
<td>$102.5K</td>
<td>619</td>
<td>1.6K</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$72.5</td>
<td>$71.4</td>
<td>$72.5</td>
<td>$100.00</td>
<td>$94.2K</td>
<td>222</td>
<td>0</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/04/24</td>
<td>$20.2</td>
<td>$18.35</td>
<td>$19.14</td>
<td>$155.00</td>
<td>$78.4K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Carvana</h3>
<p>Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.</p>
<h3>Carvana's Current Market Status</h3>
<ul>
<li>With a volume of 5,365,127, the price of CVNA is up 1.65% at $173.56. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Carvana</h3>
<p>Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $183.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $185.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their In-Line rating on Carvana, which currently sits at a price target of $157.<br />
&#x2A; An analyst from JMP Securities has revised its rating downward to Market Outperform, adjusting the price target to $200.<br />
&#x2A; An analyst from Stephens &amp; Co. downgraded its action to Overweight with a price target of $190. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carvana options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CVNA

Unpacking the Latest Options Trading Trends in Carvana

<p>Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) has outperformed the market over the past 10 years by 11.95% on an annualized basis producing an average annual return of 23.16%. Currently, Quanta Services has a market capitalization of $42.86 billion. </p>
<p><strong>Buying $100 In PWR:</strong> If an investor had bought $100 of PWR stock 10 years ago, it would be worth <strong>$786.19</strong> today based on a price of $290.89 for PWR at the time of writing.</p>
<h3>Quanta Services's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726864218_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Quanta Services Stock In The Last 10 Years

<p>Jim Cramer, the host of CNBC&#8217;s &#8220;Mad Money,&#8221; is known for his energetic and often controversial <a href="https://www.benzinga.com/markets/24/09/40905525/jim-cramer-says-he-likes-this-nancy-pelosi-portfolio-stock-very-much-and-this-ai-play-is-reasonably">takes on the stock market</a>. However, Cramer&#8217;s message on retirement planning is crystal clear and emphatic: &#8220;When it comes to managing your money, nothing is more important than retirement.&#8221;</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a>?</strong></li>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"><strong> </strong><strong>How does it compare to the average?</strong></a></strong></li>
</ul>
<p>Cramer doesn&#8217;t hold back about financial education. &#8220;There&#8217;s a gaping hole in the American education system,&#8221; he says. Sure, high schools teach chemistry, geometry and even foreign languages. You might graduate college fluent in French and capable of discussing quantum physics. But as Cramer points out, &#8220;the one thing they almost never teach … financial literacy.&#8221; He&#8217;s not talking about economics but the everyday stuff: financial planning, <a href="https://www.benzinga.com/personal-finance/24/01/36696321/will-your-1-5-million-nest-egg-last-if-you-retire-early-at-62">retirement readiness</a> and investing.</p>
<p><strong>Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"><strong> </strong><strong>re-engineers traditional banking with this new high-yield account — start saving better today.</strong></a></strong></p>
<p>Retirement planning might feel like something to tackle later, but Cramer wants you to pay attention. He says, "For those of you who are about to change the channel because the whole idea of saving for retirement puts you to sleep, hear me out … You need to know this stuff." He believes your future self will thank you for sorting out your retirement funds. Eventually, everyone will stop working – "Hopefully sooner rather than later," he quips, unless you're lucky enough to love your job.</p>
<p>Now, Cramer isn't here to sing the praises of the 401(k) as the be-all and end-all of financial planning. He knows it's a mixed bag. "Sometimes I think it's the wrong approach," he admits.&nbsp;</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/charlie-munger-100k"><strong><em>Charlie Munger said if you want to be rich, &#8220;find a way to get your hands on $100,000&#8221; — here&#8217;s what he means.</em></strong></a></em></strong></p>
<p><strong>The Good</strong></p>
<p>One of the best aspects of a 401(k) is its tax-deferred status. "You pay no taxes on what you put in and you never pay a penny of capital gains taxes on the profits you make within your 401(k)," Cramer says. This allows your investments to compound tax-free until withdrawals begin. Cramer calls compounding "the eighth wonder of the world." Investing $5,000 a year at age 30 could grow to over $511,000 by 60.</p>
<p>Another perk? Employer matching. "For every dollar you invest in your 401(k) plan, your employer might say, ‘Hey, we'll throw in 50 cents.'" Cramer urges you to use free money if your company offers it.</p>
<p><strong>Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"><strong> you can become part of the next big real estate boom today.</strong></a></strong></p>
<p><strong>The Bad</strong></p>
<p>But it's not all sunshine and rainbows. "401(k) plans can have many problems," Cramer warns. They can be riddled with hidden fees that eat away at returns. "I find that extortionate," he says. Some employers offer many choices while others limit you to just a few mutual funds.</p>
<p><strong>The Ugly</strong></p>
<p>Without employer matching, the 401(k) looks less attractive. In that case, Cramer suggests considering an IRA, which offers the same tax-deferred status and can be rolled over when changing jobs. "You can only contribute $6,500 a year to your IRA," he notes, rising to $7,500 if you're over 50. It's lower than the 401(k) limit but without some strings attached.</p>
<p><strong>Trending: The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"><strong> </strong><strong>Here are three ways to join the club.</strong></a></strong></p>
<h2 class="wp-block-heading">So, What Should You Do?</h2>
<p>Cramer's advice? Be picky. "Before you contribute money to your 401(k), make sure it gives you the option to put your cash into something worth investing in." If you're stuck with a limited range of choices, opt for a low-cost index fund that mirrors the market.</p>
<p>Cramer's not saying to ditch the 401(k) altogether, but he's <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">urging you to be smart about it.</a> Take the free money if your employer offers it, avoid high fees and choose your investments wisely.&nbsp;</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"><strong> </strong><strong>Tax deferring is their number one strategy</strong></a>.</strong></li>
<li><strong>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"><strong> </strong><strong>high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</strong></a></strong></li>
</ul>


Jim Cramer Insists: 'When It Comes To Managing Your Money, Nothing Is More Important Than Retirement' – Even If The Topic 'Puts You To Sleep'

<p>GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) has outperformed the market over the past 5 years by 63.2% on an annualized basis producing an average annual return of 77.15%. Currently, GameStop has a market capitalization of $9.28 billion. </p>
<p><strong>Buying $100 In GME:</strong> If an investor had bought $100 of GME stock 5 years ago, it would be worth <strong>$1,741.04</strong> today based on a price of $21.75 for GME at the time of writing.</p>
<h3>GameStop's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726864213_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 5 Years Ago Would Be Worth $1,700 Today

Arbutus Biopharma GAAP EPS of -$0.11 misses by $0.01, revenue of $1.73M misses by $0.03M

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Biotechnology firm <strong>Arbutus</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/abus-stock-quote/"><strong>ABUS</strong></a>) &mdash; which specializes in virology &mdash; announced a major overhaul of its business. It will dramatically <a href="https://www.marketwatch.com/story/arbutus-to-cut-staff-after-halting-hepatitis-b-virus-discovery-efforts-69dd9aaf?mod=newsviewer_click">cut headcount</a> in an effort to streamline operations and focus on its most promising therapeutic candidates. The Arbutus layoffs will result in a 40% reduction in the company&rsquo;s workforce. Though steep, ABUS stock gained about 1% in the early afternoon session.</p>



<p>According to a <em>MarketWatch</em> report, the notable aspect of the shakeup is that Arbutus &ldquo;plans to cease all Hepatitis B Virus discovery efforts, including its Im-Prove III clinical trial.&rdquo; Per the company&rsquo;s <a href="https://finance.yahoo.com/quote/ABUS/profile/">profile</a>, the biopharmaceutical firm focuses on developing novel therapeutics for chronic hepatitis B virus (cHBV) infection.</p>



<p>Instead, the biotech will focus on its candidate, imdusiran. In a statement accompanying the entity&rsquo;s second-quarter earnings report, Interim President and CEO Michael J. McElhaugh reported <a href="https://www.morningstar.com/news/globe-newswire/9197226/arbutus-reports-second-quarter-2024-financial-results-and-provides-corporate-update">impressive clinical results</a> with the therapeutic. Given the research data, McElhaugh believes that imdusiran may represent &ldquo;a potential cornerstone therapeutic in a treatment regimen to functionally cure cHBV.&rdquo;</p>



<p>The Arbutus CEO added that the company intends to focus its &ldquo;existing resources on conducting a Phase 2b clinical trial with imdusiran, assuming continued positive data. This has the potential to create a true inflection point for both Arbutus and HBV patients.&rdquo;</p>



<h2>Wall Street Views the Arbutus Layoffs Constructively</h2>



<p>While the Arbutus layoffs undoubtedly hit the impacted employees hard &mdash; the company only has 73 full-time workers, per its profile &mdash; Wall Street views the headcount reduction constructively. After an initial bout of volatility, investors began bidding up ABUS stock. Since the start of the year, shares have gained about 47%.</p>



<p>Per <em>MarketWatch</em>, the pink slips will mainly impact members of the biotech&rsquo;s discovery and administrative units. Further, the action item &ldquo;will incur a one-time restructuring charge of approximately $3 million to $4 million, which will be recorded in the third quarter.&rdquo;</p>



<p>Significantly, management mentioned with the Arbutus layoffs and the accompanying organizational changes and cost-management efforts, it &ldquo;now expects its current cash, cash equivalents and investments in marketable securities will be sufficient to fund operations into the fourth quarter of 2026.&rdquo;</p>



<p>Regarding the Q2 report, Arbutus posted a <a href="https://finance.yahoo.com/news/arbutus-biopharma-abus-reports-q2-124006030.html">quarterly loss of 11 cents</a>, slightly worse than the expected loss of 10 cents. However, the company managed to post revenue of $1.73 million for the June quarter, beating the consensus target by 12.08%. However, the latest tally is a noticeable decline from the year-ago quarter&rsquo;s sales of $4.65 million.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/08/arbutus-layoffs-2024-what-to-know-about-the-latest-abus-job-cuts/">Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a price target of $5.00. Ro...

Arbutus Biopharma: Strategic Focus and Pipeline Promise Drive Buy Rating

Keay Nakae, an analyst from Chardan Capital, reiterated the Buy rating on Arbutus Biopharma (ABUS – Research Report). The associated price target r...

Buy Rating Justified by Arbutus Biopharma's Strong Financials and Focused Clinical Strategy

Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) and keeping the price target at $5.00. E...

Promising Clinical Advances for Arbutus Biopharma's Imdusiran in Hepatitis B Treatment

Arbutus Biopharma (ABUS) has provided an update. Arbutus Biopharma Corporation, Genevant Sciences, and Moderna, Inc. have agreed to seek a delay in...

Arbutus Biopharma and Moderna Agree to Delay Patent Trial

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma Corporation, a clinical-stage company focused on developing treatments for chron...

Arbutus Biopharma Engages Investors at Key Conferences

Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Dennis Ding fr...

Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments

BNTX

GLAXF

REGN

RHHBF

RHHBY

RHHVF

Press Releases

Arbutus to Participate in Two Upcoming Investor Conferences

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus to Present Imdusiran Data at EASL Congress 2024

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Arbutus Biopharma

Arbutus Biopharma (ABUS) Forecast

Arbutus Biopharma (NASDAQ:ABUS) Stock, Quote.Headers.trade-ideas